Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06301516
Other study ID # HM20027823
Secondary ID R41MH133540
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 16, 2024
Est. completion date December 2024

Study information

Verified date March 2024
Source Virginia Commonwealth University
Contact Nicholas Thomson
Phone (804) 297-5740
Email nicholas.thomson@vcuhealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Conduct disorder (CD) is one of the most prevalent childhood psychiatric disorders. Unfortunately, there are limited treatments available for CD. The present study aims to test an innovative virtual reality intervention called Impact VR for symptom reduction in a sample of 60 youth with CD.


Description:

Within the CD diagnosis, a subset of youth (12-46%) display callous-unemotional (CU) traits (termed "limited prosocial emotions"). CU traits denote additional symptoms including a lack of remorse/guilt, a callous lack of empathy, shallow affect, and/or lack of concern about performance. Although both CD and CU traits are inextricably linked to poor outcomes for youth, there remains a scarcity of targeted interventions for CD and CU traits. One of the most significant challenges for treatment is that youth with CD are often perceived by providers as treatment-resistant and treatment disrupters. This leads to poor treatment retention and further isolation from treatment opportunities. Further, existing interventions that target antisocial behaviors more generally are costly because they require 24/7 behavioral management therapies. Impact VR is a psychoeducational intervention for improving emotion recognition and regulation, using immersive gameplay and storylines that are relevant to youth. Impact VR uses evidence-based cognitive and dialectical behavioral approaches to improve emotion regulation. At the center of Impact VR is an individualized training program that teaches youth to effectively identify emotional expressions in others.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 10 Years to 17 Years
Eligibility Inclusion Criteria: - Aged 10-17 years old - Identified through the TriNetX database as having a conduct disorder diagnosis - English speaking Exclusion Criteria: - Youth aged <10 years and >18 years old - Non-English speaking - Youth of caregivers younger than 18 years old.

Study Design


Intervention

Behavioral:
Virtual Reality
VR: The goal of the VR intervention is to provide youth an immersive, engaging, and therapeutic environment to reduce CD and CU traits
Other:
Comparative Control
Complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others.

Locations

Country Name City State
United States Virginia Commonwealth University Richmond Virginia

Sponsors (2)

Lead Sponsor Collaborator
Virginia Commonwealth University National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Callous-Unemotional traits Participants enrolled into Impact VR will be complete the first of four sessions. The four 20-minute Callous-unemotional traits will be measured using the 24-item Inventory of Callous-Unemotional Traits. Both the parent and youth reports will be completed. sessions will be completed over 4 weeks (one session per week) either in the lab, at the participant's home, school or a mutual private meeting place. Baseline, 1-month and 3-months post-randomization
Primary Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Conduct disorder Conduct disorder symptoms will be measured using the Kiddie Schedule for Affective Disorders and Schizophrenia, which is a semi-structured interview administered to the caregiver and child. Baseline, 1-month and 3-months post-randomization
Primary Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Conduct Problems Conduct problems will be assessed using parent and child reports on the Behavior Assessment System for Children, 3rd edition (BASC-3) Baseline, 1-month and 3-months post-randomization
Primary Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Emotion regulation Emotion Regulation will be assessed using parent and child reports on the Behavior Assessment System for Children, 3rd edition (BASC-3). Baseline, 1-month and 3-months post-randomization
Primary Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Emotion recognition Emotion recognition will be measured using the Penn Emotion Recognition Test, which is a computer-based task completed by the youth Baseline, 1-month and 3-months post-randomization
See also
  Status Clinical Trial Phase
Completed NCT03535805 - Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances N/A
Recruiting NCT05449002 - Digital Single Session Intervention for Youth Mental Health N/A
Withdrawn NCT02247986 - Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder Phase 1/Phase 2
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Completed NCT02485587 - Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents N/A
Completed NCT00819429 - Supplements and Social Skills Intervention Study N/A
Completed NCT00626236 - Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems Phase 2
Completed NCT01085305 - The Effectiveness of Parent-Child Interaction Therapy (PCIT) N/A
Completed NCT00000385 - Long-Term Lithium Treatment for Aggressive Conduct Disorder Phase 3
Completed NCT00250354 - A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Phase 3
Withdrawn NCT01443949 - Teenagers, Drug Addiction, and Reward and Impulse Control
Completed NCT04091633 - School Health Implementation Network: Eastern Mediterranean N/A
Completed NCT02563145 - Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents N/A
Completed NCT02766101 - Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges N/A
Completed NCT00404911 - Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth N/A
Completed NCT00051727 - Prevention of School Dropout for Mexican American Adolescents Phase 2
Completed NCT02998073 - Investigating Psychosocial Intervention Treatment Response in Justice-Involved Youth With Conduct Disorder N/A
Completed NCT03292848 - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Phase 1
Recruiting NCT06373484 - Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents N/A
Recruiting NCT05637320 - Big Feelings: A Study on Children's Emotions in Therapy N/A